May 25 (Reuters) - Aroa Biosurgery Ltd (ARX) :
- FY22 PRODUCT SALES GUIDANCE OF $30M-33M
- TOTAL REVENUE FOR FY21 WAS $22.3M
- NORMALISED LOSS BEFORE INCOME TAX FOR FY21 WAS $7.4M
- PRODUCT GROSS MARGINS EXPECTED TO IMPROVE IN H2 FY22
News: ARX Aroa Biosurgery Posts FY22 Product Sales Guidance Of $30M-33M
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.5¢ |
Change
-0.015(2.63%) |
Mkt cap ! $191.0M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 56.5¢ | 54.0¢ | $73.87K | 135.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 53.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.5¢ | 5467 | 2 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
54.0¢ |
Change
-0.015 ( 3.57 %) |
||||
| Open | High | Low | Volume | ||
| 56.0¢ | 56.0¢ | 54.0¢ | 107619 | ||
| Last updated 15.39pm 03/06/2024 ? | |||||
| ARX (ASX) Chart |